Desloratadine
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Desloratadine: H1 antihistamine → nasal cavity disease
One-Sentence Summary
Desloratadine is an H1 antihistamine marketed in Canada. The TxGNN model predicts it may be useful for nasal cavity disease, a broad and non-specific label. The data compiled for this report contain no clinical trials and 2 publications, both animal studies, so the evidence is indirect.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | nasal cavity disease |
| TxGNN Prediction Score | 0.9987 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for desloratadine are not available in the data compiled for this report. Desloratadine belongs to the H1 antihistamine class. Blocking H1 receptors reduces histamine-driven nasal symptoms such as rhinorrhea, sneezing and itching. This gives a plausible mechanistic link to disorders of the nasal cavity.
“Nasal cavity disease” is a very broad term, so the prediction is not specific. Many conditions under this label are not histamine-driven, and an antihistamine would be expected to help only the histamine-mediated ones.
No cited study examines desloratadine in this predicted disease directly. The only supporting literature consists of animal models. The evidence level is therefore capped at L5, and the prediction is treated as model-derived.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30488351 | 2019 | Animal study | Eur Arch Otorhinolaryngol | Hesperidin and thymol were tested in an ovalbumin-induced allergic rhinitis rat model. Desloratadine was not the agent studied. |
| 19769798 | 2009 | Animal study | Am J Rhinol Allergy | Loratadine plus montelukast produced decongestion in a feline nasal congestion model. The study also tested pseudoephedrine with and without desloratadine. |
Both studies are preclinical and offer only indirect support.
Canada Market Information
Health Canada lists 5 valid authorizations for desloratadine. The local records do not include approved-indication text or dosage-form details.
| DIN | Product Name |
|---|---|
| 02546019 | DESLORATADINE |
| 02243919 | AERIUS |
| 02298155 | DESLORATADINE ALLERGY CONTROL |
| 02247193 | AERIUS KIDS |
| 02309300 | AERIUS SINUS + ALLERGY |
Safety Considerations
- Drug Interactions: The interaction screen recorded 100 interacting drugs. Severity levels are not graded (“Unknown”). Examples include calcitriol, phentermine, pantoprazole, doxycycline, morphine, metformin, omeprazole, cimetidine, prednisone, simvastatin and epinephrine. These entries need clinical review before any use.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted label is broad and non-specific, and no clinical trials exist for it. The only literature is animal studies, one of which does not centre on desloratadine, so the evidence level is L5. The drug is marketed in Canada, but that does not by itself support this prediction.
To proceed, the following is needed:
- A more specific definition of the target nasal condition, and identification of which subtypes are histamine-mediated
- Clinical studies of desloratadine in that defined condition
- Mechanism-of-action data from DrugBank
- Health Canada package insert warnings and contraindications
- Severity grading of the recorded drug interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.